# Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults

> **NCT05377255** · PHASE1 · COMPLETED · sponsor: **Emergent BioSolutions** · enrollment: 24 (actual)

## Conditions studied

- Opioid Overdose

## Interventions

- **COMBINATION_PRODUCT:** 16 mg naloxone AP003
- **COMBINATION_PRODUCT:** 8 mg naloxone NARCAN Nasal Spray

## Key facts

- **NCT ID:** NCT05377255
- **Lead sponsor:** Emergent BioSolutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-28
- **Primary completion:** 2022-05-10
- **Final completion:** 2022-05-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05377255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05377255, "Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05377255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*